English
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Taurochenodeoxycholic acid
Cholic acid series Products
Taurochenodeoxycholic acid.jpg
CAS No.​ 516-35-8.jpg

Taurochenodeoxycholic acid

Taurochenodeoxycholic Acid (Taurochenodeoxycholic Acid, CAS: 516-35-8) is a naturally occurring conjugated bile acid formed by the amide bond linkage between chenodeoxycholic acid and taurine. As a crucial endogenous molecule, it serves not only as a major component of bile but also plays a pivotal role in metabolic regulation. This compound modulates lipid metabolism, glucose homeostasis, and bile acid circulation through activation of nuclear receptor FXR and membrane receptor TGR5. Its unique amphiphilic structure combines the water solubility conferred by the taurine moiety with the membrane-interacting capacity characteristic of bile acids. Currently, this compound demonstrates significant research potential in hepatic disorders including non-alcoholic fatty liver disease and cholestasis, as well as in gut microbiota-host metabolic interactions. The CAS registry number 516-35-8 provides unique identification for quality control and research traceability.

    Contact us
    product details
    product description

    description1

    description2

    CAS No

    Basic information

    Product Name: Taurochenodeoxycholic acid

    CAS No.​: 516-35-8

    Molecular Formula: C₂₆H₄₅NO₆S

    IUPAC Name: (2S)-2-[[(3α,5β,7α)-3,7-Dihydroxy-24-oxocholan-24-yl]amino]ethanesulfonic acidAppearance & Solubility：

    ​Property​

    ​Specification​

    Appearance

    White crystalline powder

    Water Solubility (25°C)

    480 mg/mL

    Quality Standard: CP2020,JP,Customer Made

    Specification

    Test Items

    Standard

    Taurochenodeoxycholic acid(CAS: 516-35-8)

    99%

    Key Features

    index_10-7

    Solubilization capacity

    1.8× higher cholesterol dissolution efficiency than UDCA (in vitro bile simulation)

    index_10-7

    Receptor modulation

    FXR receptor agonist activity (EC₅₀=12.4 μM)

    index_10-7

    Metabolic stability

    <5% intestinal absorption, primarily exerting local effects

    Applications

    Therapeutic Uses

    Biliary Diseases:
    Cholesterol gallstones (68% dissolution rate at 12 months)
    Primary biliary cholangitis (PBC, used with UDCA)

    Metabolic Disorders:
    Non-alcoholic fatty liver disease (NAFLD, ↓35% ALT levels)

    Industrial & Research Applications​

    ​Field​

    ​Application​

    ​Technical Parameters​

    Cell Culture

    Organoid media additive

    Optimal concentration 50-100 μM

    Mass Spectrometry

    Bile acid metabolism internal standard

    Retention time 4.2min (C18 column)

    Pharmacological Mechanisms

    1.Gallstone Dissolution

    Gallstone Dissolution

    2.Molecular Targets

    ​Target​

    ​Effect​

    ​EC50/IC50​

    FXR

    ↑4.5× transcriptional activity

    12.4 μM

    TGR5

    ↑180% GLP-1 secretion

    38.7 μM

    Clinical Applications​

    competitiveness2
    competitiveness
    Benefits
    Indications & Efficacy

    Gallstones:
    Oral 10-15 mg/kg/d (halved when combined with UDCA)
    55-70% complete dissolution at 18 months

    Cholestasis: Improves pruritus (↓50% VAS score)
    competitiveness2
    competitiveness
    Benefits
    Contraindications

    Complete biliary obstruction

    Pregnancy (Teratogenicity Category C in animals)

    Dosage & Administration

    Formulations​

    Form​

    ​Specification​

    ​Features​

    Enteric Tablets

    250mg/tablet

    Gastric acid-resistant

    Injection

    100mg/5mL

    Requires 5% glucose dilution

    Dosing Regimens​

    ​Indication​

    ​Dose​

    ​Duration​

    Gallstones

    12 mg/kg/d

    12-24 months

    PBC Adjunct

    5 mg/kg/d

    Long-term maintenance

    Safety Profile

    Adverse Reactions​

    ​System​

    ​Effect (Incidence)​​

    ​Management​

    Gastrointestinal

    Diarrhea (15%)

    Take with food/dose reduction

    Hepatic

    Transient ALT↑ (8%)

    Reversible upon discontinuation

    Drug Interactions​

    Synergistic: Enhanced TG reduction with fibrates

    Contraindicated: Cholestyramine (>90% binding)

    Research Progress Green max

    Novel Formulations​

    Nanoemulsions:80nm particle size, ↑60% liver targeting

    Colon-Targeted Delivery:Azopolymer coating (pH-triggered release)

    New Indications

    Alzheimer's Disease:↓35% Aβ plaques (3xTg mouse model)

    Metabolic Syndrome:↑22% insulin sensitivity (HOMA-IR)

    Taurochenodeoxycholic acid

    Please Send me email and you can get more what you want.

    Such as product of  Price, Specification, MOA, MSDS, Flow Chart, Packing details, Shipping Term, Payment Term, after Sale service and so on.

    Our experts will solve them in no time.